Lapatinib

• Background:

  Lapatinib is a tyrosine kinase inhibitor. Specifically, it interrupts the ErbB/neu and epidermal growth factor receptor (EGFR) pathways. It is an antineoplastic agent used in breast cancer research. In solid tumor cells, Lapatinib binds to the ATP-binding pocket of the protein kinase domains on EGFR/ErbB, preventing self-phosphorylation.

• Description:

  Dual EGFR/HER2 Tyrosine Kinase Inhibitor

• Product Name Alternative:

  N-[3-chloro-4-[ (3-fluorophenyl) methoxy]phenyl]-6-[5-[ (2-methylsulfonylethylamino) methyl]furan-2-yl]quinazolin-4-amine

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Growth Factor Receptor Inhibitors

• Purity:

  ≥99%

• Weight:

  0.01

• Format:

  Yellow crystalline solid

• Solubility:

  Solubility in water is 0.007 mg/ml and in 0.1N HCl is 0.001 mg/ml at 25° C

• Molecular Formula:

  C29H26ClFN4O4S

• Molecular Weight:

  581.1

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Chien A.J., et al. (2014) J. Clin. Oncol: J. Am. Clin. Oncol. 32(14): 1472–1479. 2. Dahal B.K., et al. (2010) Am. J. Resp. Critical Care Med. 181(2): 158–167.

• CAS Number:

  231277-92-2